1. Inmaculada Peñas Jiménez
OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES OCTA - European Parliament 20th October 2015
Inmaculada Peñas Jiménez
'Fighting Infectious Diseases and Global Epidemics
DG Research & Innovation European Commission

2. The role of the European Commission - Research and innovation
Develop and implement the European research and innovation policy agreed by the European Parliament and European Council. Funds research through multi-annual framework programmes for research (since 1984). Implemented through annual work programmes and call for proposals and independent peer review of proposals. The European Commission manages about 5% of total public spending in R&D in the European Union.

3. Key priorities for infectious diseases in the Health, Demographic Change and Wellbeing Theme
Emerging infectious diseases (EE)
Influenza and other emerging diseases (incl vector-borne diseases)
Anti-microbial resistance (AMR)
Poverty-related diseases (PRD)
HIV/AIDS, Tuberculosis, Malaria
Neglected Infectious diseases (NID)

4. Some figures of the research in major infectious diseases funded by the FP7 (2007-2013)

5. IDAMS € 6 million EU contribution - Start 01/09/2011 - 60 months
Some FP7 projects…
IDAMS € 6 million EU contribution - Start 01/09/ months
Is improving clinical and laboratory diagnosis and clinical management of dengue; identifying markers to differentiate dengue from other febrile illness; likelihood to evolve to a more severe disease; risk of dengue spread and maps; and developing effective and affordable early warning systems and outbreak responses
18 participants from 14 countries including from Mexico,Malaysia and Ghana
DENGUETOOLS € 6 million EU contribution - Start 01/09/ months
Developing early diagnostic tests, laboratory-based early warning systems, predictive models and risk maps better surveillance as well as developing a community-based strategy to reduce dengue incidence in school aged children
15 participants from 11 countries including Brasil, Sri Lanka and Singapore
DENFREE € 6 million EU contribution - Start 01/01/ months
Is identifying the key factors determining transmission, outcome of infection and epidemics of dengue fever, as well as developing of novel diagnostic tools to detect asymptomatic infections, and estimating the risk of virus spreading to uninfected areas
15 participants from 11 countries including Cuba, Cambodia and French Polynesia

6. The EU’s 2014-20 programme for research & innovation
What is Horizon 2020?
The EU’s programme for research & innovation
A core part of Europe 2020, Innovation Union & European Research Area
Responding to the economic crisis to invest in future jobs and growth
Addressing people’s concerns about their livelihoods, safety and environment
Strengthening the EU’s global position in research, innovation and technology

7. SC1- Health, demographic changes and wellbeing Industrial leadership
HORIZON 2020 ( )
European Research Council
Future and Emerging Technologies
Marie Skłodowska-Curie actions
Research infrastructures
Excellent science
SC1- Health, demographic changes and wellbeing
(€ 7.5 b)
Leadership in enabling and industrial technologies
Access to risk finance
Innovation in SMEs
Industrial leadership
Societal challenges
The new EU programme for research and innovation
€ 79 billion ( )

8. Industrial leadership €17bn
Excellent science €24bn
Health in H2020
Future and Emerging Technologies
Marie Skłodowska Curie
European Research Council
Research Infrastructures
Industrial leadership €17bn
Eureka Eurostars-2
LEIT Biotech
Fast Track to Innovation
Financial instruments
SC1 Health €7.5bn (of €31bn)
SME instrument
Collaborative projects
AAL-2
IMI-2
EDCTP-2

9. Infectious Diseases R&I – Collaboration for innovative solutions – Implementation
1 – Collaborative research projects
Implemented by DG RTD
2 - Horizon prize
3 – Global Initiatives
GLOPID- R ; GTBVP; World RePORT
4- Public–Private partnership
IMI2: From discovery to human testing to regulatory aspects, HTA and pharmacovigilence
5- Public–Public partnership
EDCTP2
Joint Programme on AMR
ERA-INFECT
6- Infectious Disease Finance Facility – INNOVFIN ID
jointly developed by EC and EIB

10. Infectious diseases in Horizon 2020
COLLABORATIVE RESEARCH
Priorities addressed in :
Vaccine development for poverty related and neglected infectious diseases
2014 – Tuberculosis € 25 million – 2 projects funded
2015 – HIV/AIDS € 45 million – 2 projects funded
2014 – COMPARE - Development of web based system for rapid identification, containment and mitigation of emerging infectious diseases and foodborne outbreaks by generation and comparison of genomic information on samples and pathogens across sectors, time and locations, with contextual additional data.
I-MOVE+,a scientific public health platform to identify, pilot test, use and disseminate the best study designs to measure the effectivenes (direct effect)and the impact (indirect and overall effect) of influenza and pneumococcal vaccines

11. The challenges Ageing population Increased disease burden
Unsustainable and unequal health & care systems
Health & care sector under pressure to reform

12. Who's eligible for funding?
Horizon 2020 is open to participation from across the world
By default:
Member States (including overseas departments and overseas territories)
Associated Countries
exhaustive list of countries in annex to work programme (but: no longer BRIC + Mexico in this list!)
Participants from other countries are funded in exceptional cases:
when provision is made in the call text
bilateral agreement (e.g. USA, Health challenge – NIH)
when the Commission deems it essential (case by case assessment)

13. The Horizon 2020 Health Challenge: WP 2016-2017
Understanding health, well-being & disease
Preventing disease
Treating and managing diseases
'Personalised Medicine'
Active ageing and self-management of health
Methods and data
Health care provision and integrated care
'coordination activities'
ERA-NETs , Joint Programming, Global Alliance for Chronic Diseases (GACD), Valorisation of FP7 results and other Coordination Actions
€ 930 million

14. 'PHC 2 – 2015' 'Specific challenge' 'Scope' 'Expected impact'
Understanding the call topics: example
'PHC 2 – 2015'
'Specific challenge'
'Scope'
'Expected impact'
'Type of action'

15. Topics 2016-2017 - 1.1 Understanding health, well- being and disease:
PM 01 – 2016 – Multi omics for personalised therapies [RTD]
PM 02 – New concepts in patient stratification [RTD]
PM 03 – 2016 – Diagnostic characterisation of rare diseases
PM 04 – Networking and optimising the use of population and patient cohorts at EU level [RTD]

16. Topics 2016-2017 - 1.2 Preventing diseases:
PM-05–2016: The European Human Biomonitoring Initiative [RTD]
PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases [RTD]
PM-07–2017: Promoting mental well-being in the young

17. Topics 2016-2017 - 1.3 Treating and managing diseases :
PM 08 – New therapies for rare diseases [RTD]
PM 09 – New therapies for chronic diseases [RTD]
PM 10 – Comparing the effectiveness of existing healthcare interventions in the adult population [RTD]
PM 11 – Clinical research on regenerative medicine [RTD]

18. Topics 2016-2017 - 1.4 Active ageing and self-management of health:
PM 12 – 2016 – PCP – eHealth innovation in empowering the patient [CNECT]
PM 13 – PPI for deployment and scaling up of ICT solutions for active and healthy ageing [CNECT]
PM 14 – 2016 – EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities [CNECT]
PM 15 – Personalised coaching for well-being and care of people as they age [CNECT]

19. Topics 2016-2017 - 1.5 Methods and data:
PM In-silico trials for developing and assessing biomedical products [CNECT]
PM 17 – Personalised computer models and in-silico systems for well-being [CNECT]
PM 18 – Big Data supporting Public Health policies [CNECT]
PM 19 – PPI for uptake of standards for the exchange of digitalised healthcare records [CNECT]
PM 20 - Development of new methods for improved economic evaluation and efficiency measures in the health sector [RTD]
1.6 Health care provision and integrated care:
PM Implementation research for scaling-up of evidence based innovations and good practice in Europe and middle-income countries [RTD]

20. Topics 2016-2017 - Coordination activities:
HCO 01 – Valorisation of FP7 Health and H2020 SC1 research results [RTD]
HCO 02 – Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine [RTD]
HCO 03 – Implementing the Strategic Research Agenda on Personalised Medicine [RTD]
HCO 04 – Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance [RTD]
HCO 05 – Coordinating personalised medicine research [RTD]
HCO 06 – Towards an ERA-NET for building sustainable and resilient health care models
HCO 07– Global Alliance for Chronic Diseases (GACD) [RTD]
HCO 08 – Actions to bridge the divide in European health research and innovation [RTD]

21. Topics 2016-2017 Co-ordination activities:
HCO 09 – EU m-health hub including evidence for the integration of mHealth in healthcare systems [CNECT]
HCO 10 – Support for Europe’s leading Health ICT SMEs [CNECT]
HCO 11– Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change [CNECT]
HCO 12 – Digital health literacy [CNECT]
HCO 13 – 2016 – Healthcare workforce IT skills [CNECT]
HCO 14 – EU-US interoperability roadmap [CNECT]
HCO EU eHealth Interoperability conformity assessment [CNECT]
HCO – Standardisation needs in the field of ICT for Active and Healthy Ageing [CNECT]

22. Horizon Prize for Better use of Antibiotics
The European Commission has launched the:
Horizon Prize for Better use of Antibiotics
This challenge prize is offering a cash reward of
€1 million
To the person or team who can most effectively meet the following challenge: Develop a rapid test that will allow healthcare providers to distinguish, at the point-of-care, between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without them
Upper Respiratory Tract Infections include pharyngitis, sinusitis, otitis and bronchitis
The European Commission has launched the Horizon Prize for Better Use of Antibiotics to stimulate innovative thinking and find solutions to the growing problem of antimicrobial resistance (which causes every year deaths and over €1.5 billion in healthcare expenses and productivity losses in Europe alone).
It is a challenge prize (also known as "inducement prize") offering a cash reward of €1 million to whoever can most effectively meet the following challenge:
"Develop a rapid test that will allow healthcare providers to distinguish, at the point of care, between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without them."
With such a test, doctors will be able to quickly know whether patients with upper respiratory tract infections (such as the common cold, bronchitis and otitis) can be treated safely without antibiotics. Upper respiratory tract infections are a major reason for the prescription of antibiotics, even though many of these infections are due to viruses, where antibiotics are neither effective nor necessary.
By stopping many patients from taking antibiotics needlessly, the test will prevent the side effects of such unnecessary treatment, avoid the cost of prescribing the antibiotics and, most importantly, help decrease the development of resistant bacteria.

23. GLOPID-R A Global Research Collaboration for Infectious Disease Preparedness
A global multifunder initiative
A network of research funders which aims to spark a collaborative global research response within 48 hours, after an outbreak
Key funders from Australia, Brazil, Canada, China, South Africa, US, France, UK, Sweden, Spain, Germany

24. GloPID-R objectives Facilitate exchange of information
Address scientific, legal, ethical and financial challenges
Implement a 'One Health' approach with close cooperation between human and animal health researchers
Establish a strategic agenda for research response
Connect infectious disease research networks
Create partnerships with low-income countries

25. EDCTP2 (2014 – 2024)
Broader scope: support to clinical trials to bring treatments, vaccines, diagnostics and delivery optimisation closer to the patients of HIV/AIDS, TB, malaria and neglected infectious diseases
More EU co-funding €683 million from EU Horizon at least the same amount from participating countries
Governance 28 full member countries: 14 African + 14 European countries
Publication of work plan
Political and financial up-front commitment from 14 European countries - >1.6 billion EUR
EU co-funding to match at least an equal amount from European countries

26. Capacity Development: Fellowships, Networks, Ethics, Regulatory
Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of particular relevance for Africa, including Ebola
New tools and interventions: Diagnostics, drugs, vaccines and microbicides
Capacity Development: Fellowships, Networks, Ethics, Regulatory
General rules for participation: At least 2 legal entity in EU Member States or in countries associated to Horizon 2020 and one legal entity in Sub Saharan Africa
EDCTP also supports phase IV studies to ensure that products which have shown promise in phase III trials can be developed effectively for implementation within national or regional health strategies.
This includes implementation research focused on the optimisation of health services, but limited to the delivery and increased access to products and not the full spectrum of health systems research. This includes studies on products (drugs, vaccines, microbicides, diagnostics) delivery, uptake and adherence; and strategies for equitable and full scale access to diagnostics, prevention and treatment interventions.
NIDs:
dengue/severe dengue; rabies; Human African trypanosomiasis (sleeping sickness); leishmaniases; Cysticercosis/Taeniasis; Dracunculiasis (guinea-worm disease); Echinococcosis; Foodborne trematodiases; Lymphatic filariasis; Onchocerciasis (river blindness); Schistosomiasis; Soil-transmitted helminthiases; Buruli ulcer; Leprosy (Hansen disease); Trachoma; Yaws; diarrhoeal infections; lower respiratory infections and infectious diseases of particular relevance for Africa

27. Get prepared! Free of charge services to assist you:
Call text, guide for applicants, FAQs: Participant portal
Practical information & assistance: National Contact Points (NCPs), Enterprise Europe Network (EEN)
Find partners, training, brokerage: Fit for Health 2.0
Projects funded in FP7 Health: EU Health projects database
IP questions and advices: IPR helpdesk
SME regulatory one stop shop: EMA SME office
Become evaluator - select the best projects

28. Thank you www.ec.europa/research/horizon2020